A. MENARINI BIOMARKERS SINGAPORE

A. Menarini GmbH (Menarini) is the Swiss subsidiary of the MENARINI Group, Italy's largest pharmaceutical company in Florence. The family-owned pharmaceutical group ranks among the 20 largest pharmaceutical companies in Europe. With 17’000 employees worldwide, Menarini is present in more than 100 countries. Menarini’s R&D is based in Italy, Germany and Spain. Menarini sells original products in Primary and Specialty Care. Another focus is Consumer Health and Aesthetic Medicine. In Switzerland, we are located in Zurich Oerlikon, just a 7-minute walk away from the third most frequented train station in Switzerland. The young Swiss affiliate is composed of 40 people – about half in the Sales team. Our focus is Primary Care in cardiovascular diseases, allergy, gout arthritis, infectiology and new also in the field of Specialty Care in aesthetic medicine.

Menarini is the world's largest Italian biopharmaceutical company with a heritage of over 128 years, operating across 100+ countries globally. Our vision in Asia-Pacific is to be a leading provider of essential healthcare brands to enhance the lives of people in the region. We operate across the entire commercial value chain, from regulatory approval to lifecycle management, with a diverse portfolio of proprietary and partnered brands in key therapeutic areas such as Dermatology, Select Specialty Care, Allergy/Respiratory, Cardiovascular, Men's Health, and Consumer Health.

The Menarini Group is a leading Italian pharmaceutical company committed to delivering high-quality, innovative medicines and services globally. With a focus on research, collaboration, and internationalization, we strive to meet the needs of physicians and patients alike. Our commitment to quality is evident in our efficient systems and processes, which have created a unique standard for ensuring excellence throughout all phases of drug manufacturing. With a consolidated turnover of 3,750 billion euro in 2020 and a presence in 140 countries, we employ over 17,650 people across 10 R&D centers and 18 manufacturing sites. In 2020, we produced 581 million packs of product.